Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 GenprexLotus PharmaceuticalsIMVChiasmaMetacrine
SymbolNASDAQ:GNPXOTCMKTS:LTUSNASDAQ:IMVNASDAQ:CHMANASDAQ:MTCR
Price Information
Current Price$3.79$0.05$2.79$3.05$4.17
52 Week RangeBuyN/ABuyBuyBuy
MarketRank™
Overall Score1.20.00.81.71.7
Analysis Score3.50.03.33.53.5
Community Score2.40.00.62.54.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.01.70.8
Earnings & Valuation Score0.00.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyBuy
Consensus Price Target$6.00N/A$8.54$11.67$20.67
% Upside from Price Target58.31% upsideN/A206.15% upside282.51% upside395.60% upside
Trade Information
Market Cap$164.02 million$117.78 million$188.68 million$176.42 million$109.29 million
Beta-0.571.291.691.59N/A
Average Volume1,435,554161,094259,1071,619,48178,081
Sales & Book Value
Annual RevenueN/AN/A$430,000.00N/AN/A
Price / SalesN/AN/A438.80N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.15 per shareN/A$0.10 per share$2.04 per shareN/A
Price / BookN/AN/A27.90N/AN/A
Profitability
Net Income$-10,650,000.00N/A$-20,620,000.00$-36,320,000.00N/A
EPS($0.67)N/A($0.41)($1.06)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E Ratio∞∞N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-9,661.54%N/AN/A
Return on Equity (ROE)-81.49%N/A-180.04%-83.82%N/A
Return on Assets (ROA)-79.54%N/A-91.98%-56.55%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.20%N/A0.09%
Current Ratio60.40%N/A7.03%9.44%27.04%
Quick Ratio58.58%N/A7.03%8.95%27.04%
Ownership Information
Institutional Ownership Percentage12.50%N/A20.74%71.29%52.31%
Insider Ownership Percentage13.05%N/AN/A5.50%N/A
Miscellaneous
Employees8233778535
Shares Outstanding43.28 million2.94 billion67.63 million57.84 million26.21 million
Next Earnings Date5/13/2021 (Estimated)N/A5/21/2021 (Estimated)5/6/2021 (Estimated)6/17/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Analysts Expect Metacrine, Inc. (NASDAQ:MTCR) Will Announce Earnings of -$0.52 Per Share Analysts Expect Metacrine, Inc. (NASDAQ:MTCR) Will Announce Earnings of -$0.52 Per Share
americanbankingnews.com - April 18 at 4:58 PM
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roches Asthma Drug - BenzingaThe Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug - Benzinga
benzinga.com - April 13 at 9:03 AM
Appointments and advancements for April 6, 2021 | 2021-04-06 - BioWorld OnlineAppointments and advancements for April 6, 2021 | 2021-04-06 - BioWorld Online
bioworld.com - April 6 at 10:52 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors - GlobeNewswireMetacrine Appoints Dr. Julia C. Owens to Its Board of Directors - GlobeNewswire
globenewswire.com - April 6 at 12:35 AM
Metacrine (MTCR) Appoints Dr. Julia C. Owens to Its Board of Directors - StreetInsider.comMetacrine (MTCR) Appoints Dr. Julia C. Owens to Its Board of Directors - StreetInsider.com
streetinsider.com - April 5 at 7:34 PM
METACRINE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.comMETACRINE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - April 5 at 7:34 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors - BioSpaceMetacrine Appoints Dr. Julia C. Owens to Its Board of Directors - BioSpace
biospace.com - April 5 at 7:34 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of DirectorsMetacrine Appoints Dr. Julia C. Owens to Its Board of Directors
finance.yahoo.com - April 5 at 7:34 PM
RBC Capital Keeps Their Buy Rating on Metacrine (MTCR) - Analyst RatingsRBC Capital Keeps Their Buy Rating on Metacrine (MTCR) - Analyst Ratings
analystratings.com - March 21 at 10:20 PM
Form 8-K Metacrine, Inc. For: Mar 16 - StreetInsider.comForm 8-K Metacrine, Inc. For: Mar 16 - StreetInsider.com
streetinsider.com - March 19 at 12:45 AM
METACRINE, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.comMETACRINE, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - March 18 at 7:44 AM
Metacrine Inc to Host Earnings Call - Yahoo FinanceMetacrine Inc to Host Earnings Call - Yahoo Finance
finance.yahoo.com - March 18 at 7:44 AM
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswireMetacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire
globenewswire.com - March 18 at 7:44 AM
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsMetacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 18 at 7:44 AM
Metacrine Inc to Host Earnings CallMetacrine Inc to Host Earnings Call
finance.yahoo.com - March 18 at 7:44 AM
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - Yahoo FinanceMetacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - Yahoo Finance
finance.yahoo.com - March 12 at 11:57 PM
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ...Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ...
apnews.com - March 12 at 6:56 PM
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference - GlobeNewswireMetacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference - GlobeNewswire
globenewswire.com - March 11 at 7:07 AM
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - Northeast Mississippi Daily JournalMetacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - Northeast Mississippi Daily Journal
djournal.com - March 11 at 7:07 AM
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference CallMetacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
finance.yahoo.com - March 11 at 7:07 AM
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG ConferenceMetacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference
finance.yahoo.com - March 11 at 7:07 AM
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASHOn-track for Interim Analysis Readout in the Fourth Quarter of 2021 - BioSpaceMetacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASHOn-track for Interim Analysis Readout in the Fourth Quarter of 2021 - BioSpace
biospace.com - March 10 at 12:25 AM
Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH - StreetInsider.comMetacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH - StreetInsider.com
streetinsider.com - March 9 at 2:23 PM
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH - GlobeNewswireMetacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH - GlobeNewswire
globenewswire.com - March 9 at 9:21 AM
Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference - Yahoo FinanceMetacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference - Yahoo Finance
finance.yahoo.com - March 2 at 2:24 PM
DateCompanyBrokerageAction
1/26/2021GenprexNational SecuritiesInitiated Coverage
5/26/2020GenprexNoble FinancialReiterated Rating
4/22/2020GenprexAlliance Global PartnersInitiated Coverage
4/1/2019GenprexMaxim GroupDowngrade
3/18/2021IMVLeede Jones GabReiterated Rating
3/18/2021IMVNational BanksharesLower Price Target
3/18/2021IMVRaymond JamesReiterated Rating
8/12/2020IMVHC WainwrightReiterated Rating
8/7/2020IMVNational Bank FinancialDowngrade
7/21/2020IMVIndustrial Alliance SecuritiesInitiated Coverage
7/14/2020IMVWells Fargo & CompanyBoost Price Target
5/25/2020IMVEchelon Wealth PartnersReiterated Rating
3/31/2020IMVB. RileyDowngrade
1/11/2021ChiasmaPiper SandlerLower Price Target
8/13/2020ChiasmaJefferies Financial GroupInitiated Coverage
3/17/2020ChiasmaCantor FitzgeraldReiterated Rating
7/31/2019ChiasmaPiper Jaffray CompaniesInitiated Coverage
7/24/2019ChiasmaBrookline Capital ManagementReiterated Rating
2/19/2019ChiasmaRoth CapitalInitiated Coverage
3/22/2021MetacrineCanaccord GenuityReiterated Rating
3/21/2021MetacrineRoyal Bank of CanadaReiterated Rating
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.